PQNT0.300%
as of Jul 21
SGP
GrowthSpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost.
Close · 3M
-26.18%
Held by 1 AI ETF
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals1
Win rate100% (1/1)
Avg buy return+8.57%
PQNT · Weight decrease · 2d
Pictet Asset Management's PQNT, employing AI signals integrated with factor exposures across its broad portfolio of approximately 300 international developed-market stocks, has systematically reduced its weighting in SpyGlass Pharma (SGP). The observed consecutive weight decrease from 0.3700% on June 24th to 0.3100% by July 2nd, occurring within its periodic rebalancing cycle, suggests a sustained negative output from its AI-driven assessment. This divestment trend, enacted at the current $19.47 price point, is consistent with the AI overlay detecting adverse signals such as SGP's -33.7% 90-day return, likely impacting the fund's momentum and valuation factors. The move highlights the fund's disciplined method of shedding exposure to a Health Care sector stock exhibiting clear downturns in its assessed characteristics.
weight 0.340% → 0.310% (-0.030 pp)·stock up 4.3% in the 30 days before
Jul 2·entry $19.15·now $20.02
+4.54%
since Jul 2
PQNT · Weight increase · 2d
SpyGlass Pharma, Inc. (SGP) currently trades at $18.09, closely approaching its 52-week low of $17.97, reflecting a 30-day decline of 21.1% and a one-year decline of 31.5% from its $29.68 peak. This price trajectory, placing SGP at 61% of its 52-week high, indicates that Pictet Asset Management's PQNT, an AI-managed ETF combining AI signals with factor exposures including valuation and sentiment, identified a specific opportunity within its international developed-market universe. Following an initial reduction in early June, the fund's systematic process prompted a consecutive weight increase in SGP, moving from 0.41% on June 8 to 0.42% on June 11, and then further to 0.43% by June 12. This reallocation suggests the AI overlay, integrating updated sentiment or fundamental data, identified a buying signal for the Health Care stock at its current significantly discounted price levels.
weight 0.410% → 0.430% (+0.020 pp)·stock down 22.6% in the 30 days before
Jun 12·entry $18.44·now $20.02Drifting
+8.57%
since Jun 12
PQNT · Weight decrease · 2d
weight 0.440% → 0.400% (-0.040 pp)·stock down 20.2% in the 30 days before
Jun 4·entry $19.47·now $20.02
+2.82%
since Jun 4
PQNT · Weight decrease · 2d
The AI-managed ETF is likely reducing its SGP weight due to its algorithms detecting a sustained negative shift in the company's fundamentals, such as adverse clinical trial results or increased regulatory hurdles specific to SpyGlass Pharma. This persistent selling indicates the AI perceives enduring downside risk or a significantly diminished growth outlook. For a retail investor, this systematic reduction by an advanced fund should serve as a strong cautionary signal to investigate recent company news thoroughly and re-evaluate their investment in SGP.
weight 0.470% → 0.450% (-0.020 pp)·stock down 5.3% in the 30 days before
Apr 29·entry $22.13·now $20.02
-9.53%
since Apr 29
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.